Cited 24 times since 2019 (3.6 per year) source: EuropePMC Cancer treatment reviews, Volume 74, 19 3 2019, Pages 21-28 Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R
CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Polypharmacy is a well-known problem in advanced cancer causing potential drug-drug interactions (DDIs), which, in turn, may limit the therapeutic value of CDK4/6 inhibitors. Therefore, understanding the mechanisms underlying potential DDIs in patients taking CDK4/6 inhibitors may be useful in decision-making processes and represent an important step towards treatment personalization. The present review is aimed at describing the potential DDIs that might occur in breast cancer patients receiving CDK4/6 inhibitors based on direct evidence from the literature and mechanistic considerations tailored on specific class of drugs used in combination.
